Tarsus Pharmaceuticals Appoints David Pyott to Board of Directors
Tarsus Pharmaceuticals announced the appointment of David Pyott, former Chairman and CEO of Allergan, to its Board of Directors.
Trade with 70% Backtested Accuracy
Analyst Views on TARS
About TARS
About the author
Tarsus Pharmaceuticals Appoints New Board Member
- New Board Member: Tarsus Pharmaceuticals has appointed David E. I. Pyott to its Board of Directors, who brings extensive leadership experience in the global biopharmaceutical industry, having transformed Allergan from a $1 billion eye care business into a $7 billion global leader as CEO.
- Strategic Growth Catalyst: Pyott's appointment is seen as a significant move to advance Tarsus's XDEMVY product and pipeline, expected to drive long-term growth and innovation, thereby strengthening the company's market position in eye care.
- Industry Influence: During his 17-year tenure at Allergan, Pyott successfully navigated market complexities while maintaining long-term growth, earning recognition as one of Harvard Business Review's “100 Best Performing CEOs in the World,” highlighting his influence in the industry.
- Diverse Background: In addition to his role at Tarsus, Pyott serves on the boards of other biopharmaceutical companies and holds multiple degrees in international law, medicine, and business management, showcasing his expertise and leadership potential across various fields.
From Olema to Insmed: Do These Soaring Biotechs Still Present a Good Investment Opportunity?
Biotech Sector Performance: The biotech sector is experiencing significant stock surges and advancements in trials and regulatory filings, highlighting the importance of distinguishing between short-term price fluctuations and long-term value for investors.
Notable Stock Highlights: Several biotech companies, including Olema Pharmaceuticals, Owlet Inc., and Rigel Pharmaceuticals, have reached new 52-week highs, driven by positive trial results and strategic offerings.
Upcoming Developments: Companies like Jazz Pharmaceuticals and Tarsus Pharmaceuticals are preparing for important regulatory submissions and clinical trials, indicating ongoing innovation and potential market impact.
Financial Outlooks: Firms such as Natera and Kiniksa Pharmaceuticals have provided updated revenue guidance for 2025, reflecting growth expectations and strategic advancements in their respective fields.
Tarsus Pharmaceuticals, Inc. (TARS) Posts Q3 Loss but Exceeds Revenue Projections
Quarterly Performance: Tarsus Pharmaceuticals reported a quarterly loss of $0.30 per share, better than the expected loss of $0.35, and significantly improved from a loss of $0.61 per share a year ago, marking a 14.29% earnings surprise.
Revenue Growth: The company achieved revenues of $118.7 million for the quarter, exceeding the Zacks Consensus Estimate by 2.80% and showing substantial growth from $48.12 million in the same quarter last year.
Stock Outlook: Tarsus Pharmaceuticals has seen a 26% increase in its stock price since the beginning of the year, outperforming the S&P 500, but the future performance will depend on management's commentary and earnings estimate revisions.
Industry Context: The Medical - Biomedical and Genetics industry, where Tarsus operates, ranks in the top 39% of Zacks industries, indicating a favorable outlook, while Codexis, another company in the same sector, is set to report its quarterly results soon.
Tarsus Sets Q4 Sales Goal of $140M–$145M Amidst Increased XDEMVY Adoption and Pipeline Development
Earnings Performance: Tarsus Pharmaceuticals reported Q3 2025 net product sales of $118.7 million for XDEMVY, with over 103,000 bottles dispensed, exceeding previous guidance. The company anticipates Q4 sales between $140 million to $145 million and annual revenue of $440 million to $445 million.
Market Engagement: CEO Bobak Azamian noted significant growth in physician engagement, with over 20,000 doctors prescribing XDEMVY, and a 20% increase in weekly prescribers. The direct-to-consumer (DTC) campaign has also driven a 90% increase in website visits and a 42% rise in unaided awareness.
Pipeline Development: Tarsus plans to initiate a Phase II trial for ocular rosacea by the end of the year and expects to start a Phase 2b study for Lyme disease prevention in 2026, indicating a strong commitment to expanding its product offerings.
Operational Outlook: Management expressed confidence in sustaining growth despite potential challenges from seasonal demand fluctuations and rising operating expenses due to increased DTC investments. Analysts showed cautious optimism regarding the sustainability of growth and repeat prescriptions.
HC Wainwright & Co. Reaffirms Buy Rating for Tarsus Pharmaceuticals and Increases Price Target to $88
Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders, helping them stay informed and make timely decisions in the stock market.
Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, benefiting from exclusive stories and insights provided by Benzinga reporters.
Noteworthy TARS Put and Call Options Set for November 21st
Put Contract Overview: The $50.00 put contract for TARS has a bid of $1.40, allowing investors to buy shares at a cost basis of $48.60, which is a 10% discount from the current price of $55.51. There is a 67% chance the contract may expire worthless, offering a potential 2.80% return on cash commitment.
Call Contract Overview: The $60.00 call contract has a bid of $0.50, allowing investors to sell shares at that price, which represents an 8% premium over the current stock price. There is a 63% chance this contract may also expire worthless, providing a potential 0.90% additional return.
Volatility Insights: The implied volatility for the put contract is 65%, while for the call contract it is 53%. The actual trailing twelve-month volatility is calculated at 49%.
YieldBoost Concept: The article discusses the concept of YieldBoost, highlighting potential returns from both put and call contracts, and encourages investors to track these options and their changing odds on Stock Options Channel's website.
Tarsus Pharmaceuticals Appoints New Board Member
- New Board Member: Tarsus Pharmaceuticals has appointed David E. I. Pyott to its Board of Directors, who brings extensive leadership experience in the global biopharmaceutical industry, having transformed Allergan from a $1 billion eye care business into a $7 billion global leader as CEO.
- Strategic Growth Catalyst: Pyott's appointment is seen as a significant move to advance Tarsus's XDEMVY product and pipeline, expected to drive long-term growth and innovation, thereby strengthening the company's market position in eye care.
- Industry Influence: During his 17-year tenure at Allergan, Pyott successfully navigated market complexities while maintaining long-term growth, earning recognition as one of Harvard Business Review's “100 Best Performing CEOs in the World,” highlighting his influence in the industry.
- Diverse Background: In addition to his role at Tarsus, Pyott serves on the boards of other biopharmaceutical companies and holds multiple degrees in international law, medicine, and business management, showcasing his expertise and leadership potential across various fields.
From Olema to Insmed: Do These Soaring Biotechs Still Present a Good Investment Opportunity?
Biotech Sector Performance: The biotech sector is experiencing significant stock surges and advancements in trials and regulatory filings, highlighting the importance of distinguishing between short-term price fluctuations and long-term value for investors.
Notable Stock Highlights: Several biotech companies, including Olema Pharmaceuticals, Owlet Inc., and Rigel Pharmaceuticals, have reached new 52-week highs, driven by positive trial results and strategic offerings.
Upcoming Developments: Companies like Jazz Pharmaceuticals and Tarsus Pharmaceuticals are preparing for important regulatory submissions and clinical trials, indicating ongoing innovation and potential market impact.
Financial Outlooks: Firms such as Natera and Kiniksa Pharmaceuticals have provided updated revenue guidance for 2025, reflecting growth expectations and strategic advancements in their respective fields.
Tarsus Pharmaceuticals, Inc. (TARS) Posts Q3 Loss but Exceeds Revenue Projections
Quarterly Performance: Tarsus Pharmaceuticals reported a quarterly loss of $0.30 per share, better than the expected loss of $0.35, and significantly improved from a loss of $0.61 per share a year ago, marking a 14.29% earnings surprise.
Revenue Growth: The company achieved revenues of $118.7 million for the quarter, exceeding the Zacks Consensus Estimate by 2.80% and showing substantial growth from $48.12 million in the same quarter last year.
Stock Outlook: Tarsus Pharmaceuticals has seen a 26% increase in its stock price since the beginning of the year, outperforming the S&P 500, but the future performance will depend on management's commentary and earnings estimate revisions.
Industry Context: The Medical - Biomedical and Genetics industry, where Tarsus operates, ranks in the top 39% of Zacks industries, indicating a favorable outlook, while Codexis, another company in the same sector, is set to report its quarterly results soon.
Tarsus Sets Q4 Sales Goal of $140M–$145M Amidst Increased XDEMVY Adoption and Pipeline Development
Earnings Performance: Tarsus Pharmaceuticals reported Q3 2025 net product sales of $118.7 million for XDEMVY, with over 103,000 bottles dispensed, exceeding previous guidance. The company anticipates Q4 sales between $140 million to $145 million and annual revenue of $440 million to $445 million.
Market Engagement: CEO Bobak Azamian noted significant growth in physician engagement, with over 20,000 doctors prescribing XDEMVY, and a 20% increase in weekly prescribers. The direct-to-consumer (DTC) campaign has also driven a 90% increase in website visits and a 42% rise in unaided awareness.
Pipeline Development: Tarsus plans to initiate a Phase II trial for ocular rosacea by the end of the year and expects to start a Phase 2b study for Lyme disease prevention in 2026, indicating a strong commitment to expanding its product offerings.
Operational Outlook: Management expressed confidence in sustaining growth despite potential challenges from seasonal demand fluctuations and rising operating expenses due to increased DTC investments. Analysts showed cautious optimism regarding the sustainability of growth and repeat prescriptions.
HC Wainwright & Co. Reaffirms Buy Rating for Tarsus Pharmaceuticals and Increases Price Target to $88
Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders, helping them stay informed and make timely decisions in the stock market.
Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, benefiting from exclusive stories and insights provided by Benzinga reporters.
Noteworthy TARS Put and Call Options Set for November 21st
Put Contract Overview: The $50.00 put contract for TARS has a bid of $1.40, allowing investors to buy shares at a cost basis of $48.60, which is a 10% discount from the current price of $55.51. There is a 67% chance the contract may expire worthless, offering a potential 2.80% return on cash commitment.
Call Contract Overview: The $60.00 call contract has a bid of $0.50, allowing investors to sell shares at that price, which represents an 8% premium over the current stock price. There is a 63% chance this contract may also expire worthless, providing a potential 0.90% additional return.
Volatility Insights: The implied volatility for the put contract is 65%, while for the call contract it is 53%. The actual trailing twelve-month volatility is calculated at 49%.
YieldBoost Concept: The article discusses the concept of YieldBoost, highlighting potential returns from both put and call contracts, and encourages investors to track these options and their changing odds on Stock Options Channel's website.
